Krystal Biotech(NASDAQ) KRYS

Krystal makes gene therapies to treat rare and serious diseases. Its technology helps patients by delivering healthy genes directly to cells using a modified virus. These treatments can be applied as drops, gels, or inhaled sprays at home.

What Krystal Offers

• VYJUVEK: Topical gel for treating dystrophic epidermolysis bullosa (DEB), a condition where skin blisters and tears easily.
• Respiratory Pipeline: Inhaled therapies like KB407 for cystic fibrosis and KB408 for lung disease caused by protein deficiency.
• Ophthalmic Drops: Eye treatments for complications of DEB and neurotrophic keratitis, which causes damage to the clear front part of the eye.
• Aesthetic Injectables: Genetic treatments developed by Jeune Aesthetics to address skin aging, wrinkles, and elasticity.
• Oncology Treatments: Immunotherapies like KB707 designed to help the body fight solid tumors in the lungs and skin.

Recent Growth and Strategic Steps

• Launched VYJUVEK in the United States in 2023 for patients with DEB aged six months and older.
• Expanded international reach in 2025 by launching VYJUVEK in Germany, France, and Japan.
• Sold a Rare Pediatric Disease Priority Review Voucher for $100 million in the third quarter of 2023.
• Opened AASTRA in 2023, a second commercial-scale manufacturing facility to support the growing product pipeline.
• Entered distribution agreements in 2026 with regional partners in Central Europe, the Middle East, Turkey, and Israel.

What Makes the Platform Different?

Krystal uses a modified herpes simplex virus-1 (HSV-1) that can be given multiple times without the body rejecting it. This platform allows for non-invasive delivery and can carry large genetic payloads to treat complex diseases.

The Financial Scorecard

• Net product revenue reached $730.3 million between the 2023 launch and February 2026.
• Quarterly revenue rose to $107.1 million in Q4 2025, up 17.5% from the previous year.
• Net income grew to $51.4 million in Q4 2025, a 13% increase compared to Q4 2024.
• Operating cash flow reached $77.5 million in Q4 2025, up 46.7% year-over-year.
• Market capitalization grew to $7.1 billion by the end of 2025, a 58.4% increase from 2024.

Bottom Line

Krystal has transitioned from a research firm to a global commercial business with its own manufacturing and distribution. Its ability to use a single technology for skin, lung, and eye diseases drives its current expansion.